Cinven buys Mercury Pharma from HgCapital for $732 mln
LONDON Aug 17 (Reuters) - Investor HgCapital has sold British pharmaceutical company Mercury Pharma to private equity firm Cinven for 465 million pounds ($732 million).
"The realisation of Mercury Pharma marks the continued development of HgCapital's investment focus in the healthcare sector," said HgCapital's head of healthcare, Philipp Schwalber, in a statement on Friday.
"We continue to seek out businesses that enjoy niches of secular growth despite the challenges facing much of the healthcare space," he said.
HgCapital bought the 25-year-old pharmaceutical firm, which sells niche prescription off-patent products in the UK, Ireland and the Netherlands, in 2009.
It said its listed investment trust HgCapital Trust expects to receive 35.4 million pounds in cash on the sale completion and further potential proceeds of 1 million pounds over the next 30 months.
- Tweet this
- Share this
- Digg this
- U.S. drug regulator approves headband device to prevent migraines
- Malaysia military source says missing jet veered to west
- UPDATE 3-Republican Party wins Florida congressional seat in special election
- Wild theories fill void left by missing Malaysian plane
- When Zach met Barack: pitching Obamacare online
Consumer inflation and industrial output data on Wednesday will likely offer little evidence of a respite from high inflation and weak economic growth before a general election that begins next month. Full Article